Unusual Volume: Windstream Holdings (NASDAQ:WIN), New York Mortgage Trust (NASDAQ:NYMT), Apollo Education Group (NASDAQ:APOL), Myriad Genetics (NASDAQ:MYGN)

TheStreet Ratings team rates Windstream Holdings, Inc. (NASDAQ:WIN) as a Buy with a ratings score of B-. Windstream Holdings, Inc. (NASDAQ:WIN) stock performance was 2.47% in last session and finished the day at $8.71. Traded volume was 24.23million shares in the last session and the average volume of the stock remained 8.78million shares. The beta of the stock remained 0.83. Windstream Holdings, Inc. (NASDAQ:WIN) insider ownership is 0.80%.

Shares of New York Mortgage Trust Inc (NASDAQ:NYMT) saw a significant growth in short interest in the month of January. As of March 14th, there was short interest totaling 5,030,182 shares, a growth of 50.2% from the February 28th total of 3,348,499 shares. New York Mortgage Trust Inc (NASDAQ:NYMT) dropped -2.69 percent to $7.61 Wednesday on volume of 21.30million shares. The intra-day range of the stock was $7.47 to $7.61. New York Mortgage Trust Inc (NASDAQ:NYMT) has a market capitalization of $576.13million.

An Arizona House panel Wednesday axed a proposed property-tax break for a Phoenix-based private Christian university after lawyers for the legislature said it was appeared to be unconstitutional. Senate Bill 1303 was drafted to only benefit Grand Canyon and drew objections from the University of Phoenix. It passed the Senate in February. The Apollo Education Group Inc (NASDAQ:APOL), parent company of the private University of Phoenix, opposed the bill, with a company executive testifying that it could “create winners and losers in the private sector.” Apollo Education Group Inc (NASDAQ:APOL)’s stock on Apr 02, 2014 reported a decrease of -8.82% to the closing price of $32.06. Its fifty two weeks range is $16.54 -$35.92. The total market capitalization recorded $3.61billion. The overall volume in the last trading session was 10.88million shares. In its share capital, APOL has 112.69million outstanding shares.

Small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ:MYGN) jumped to a five year high on Wednesday thanks to good news that the government will be paying a heftier reimbursement for its main test than previously feared, meaning its worth taking a closer look at the stock along with small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). On Wednesday, shares of Myriad Genetics, Inc. (NASDAQ:MYGN) advanced 11.47% to close the day at $39.18. Company return on investment (ROI) is 19.50% and its monthly performance is recorded as 4.76%. Myriad Genetics, Inc. (NASDAQ:MYGN) quarterly revenue growth is 86.75%.